Bromocriptine - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH.

30 May 2009 The usual, initial therapy of patients with chronic lymphocytic leukemia (CLL) involves alkylating agents, corticosteroids, purine analogs, and monoclonal antibodies. The combination of these agents may lead to high complete and overall response ... Read more...

Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.

12 Mar 2009 The aim of this study was to evaluate the safety and tolerability of overnight switching from ergot-derived dopamine agonists such as cabergoline to equivalent doses of pramipexole in patients with Parkinson's disease. The safety of overnight ... Read more...

Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

27 Feb 2009 Neuroleptic malignant syndrome (NMS) is a relatively uncommon side effect that may develop after a recent increase in the therapeutic dose of an antipsychotic medication or the addition of a new agent in therapeutic doses. CASE REPORT: We report a ... Read more...

Latest indexed articles for 'Bromocriptine - Administration & dosage'

These are the very latest articles for this heading:

• Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough. 14 Jun 2009
• Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. 30 May 2009
• Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. 12 Mar 2009
• Correspondence (letter to the editor): Case numbers are tiny. 11 Mar 2009
• Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. 27 Feb 2009
• Bromocriptine use and the risk of valvular heart disease. 13 Feb 2009
• Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. 2 Feb 2009
• Pregnancy rate following bromocriptine treatment in infertile women with galactorrhea. 30 Jan 2009
• Smoking in pregnancy and lactation: a review of risks and cessation strategies. 22 Jan 2009
• Collaborative work on evaluation of ovarian toxicity. 15) Two- or four-week repeated-dose studies and fertility study of bromocriptine in female rats. 30 Dec 2008
• Recovery from peripartum cardiomyopathy after treatment with bromocriptine. 13 Oct 2008
• [The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine] 29 Jun 2008
• [Digital ischemia related to bromocriptin] 22 Jun 2008
• Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia. 5 May 2008
• Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature. 30 Jan 2008
• Solid lipid nanoparticles as delivery systems for bromocriptine. 2008
• Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. 30 Dec 2007
• Low intensity laser therapy is comparable to bromocriptine-evening primrose oil for the treatment of cyclical mastalgia in Egyptian females. 30 Aug 2007
• Prevention of salt-induced hypertension by an analog of gamma-melanocyte-stimulating hormone in the rat. 30 Jul 2007
• Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects. 3 Jul 2007

See a longer list of these articles.

Technical information about 'Bromocriptine'

Definition: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.

Chemical name: Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-

Registry Number: 25614-03-3

Descriptor UI: D001971

Alternative terms: Bromocriptine; 2-Bromo-alpha-ergokryptine; 2 Bromo alpha ergokryptine; Bromocryptin; 2-Bromoergokryptine; 2 Bromoergokryptine; Bromocriptin; 2-Bromoergocryptine; 2 Bromoergocryptine; 2-Bromo-alpha-ergocryptine; 2 Bromo alpha ergocryptine; 2-Bromoergocryptine Mesylate; 2 Bromoergocryptine Mesylate; Mesylate, 2-Bromoergocryptine; Bromocriptine Mesylate; Mesylate, Bromocriptine; 2-Bromoergocryptine Methanesulfonate; 2 Bromoergocryptine Methanesulfonate; Methanesulfonate, 2-Bromoergocryptine; CB-154; CB 154; CB154; Parlodel;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Hormone Antagonists; Dopamine Agonists;

Tree Number: D03.132.327.412.100; D03.549.439.131; D03.549.562.100;

Online Note: use BROMOCRIPTINE to search 2-BROMOERGOCRYPTINE 1975-80

History Note: 81; was 2-BROMOERGOCRYPTINE 1978-80, was 2-BROMOERGOCRYPTINE see under ERGOTOXINE 1977, was 2-BROMOERGOCRYPTINE see under ERGOLINES 1975-76